BMMSC-sEV treatment could increase the level of platelet-derived growth factor receptor-β (PDGFRβ), an angiogenetic factor, more than BMMSC treatment itself within 24 h after myocardial infarction in rats (Wang et al., 2021). This evidence concerns the gene PDGFRB and myocardial infarction.